普洛药业(000739) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥1,233,756,827.92, reflecting a slight increase of 0.08% year-on-year[8] - Net profit attributable to shareholders decreased by 43.19% to ¥33,139,694.68 compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,042,180.71, down 61.69% year-on-year[8] - Basic earnings per share were ¥0.03, a decrease of 40.00% compared to the same period last year[8] - The weighted average return on net assets was 1.25%, down 1.04 percentage points year-on-year[8] Assets and Shareholder Information - Total assets at the end of the reporting period reached ¥5,662,625,081.30, an increase of 0.78% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company increased by 3.74% to ¥2,714,471,927.07[8] - The company reported a total of 54,627 common shareholders at the end of the reporting period[12] - The top ten shareholders held a combined 49.65% of the company's shares, with the largest shareholder holding 24.71%[12] Cash Flow and Financial Changes - The net cash flow from operating activities for the year-to-date was ¥286,946,362.43, a significant increase of 15,177.79%[8] - Cash and cash equivalents net increase was 44.30 million, a significant improvement compared to a decrease of 114.20 million in the previous period[16] - The net cash received from the disposal of fixed assets was 17.12 million, a substantial increase of 22885.90% compared to the previous period[16] - The company received 14.32 million in cash related to financing activities, a decrease of 80.12% compared to the previous period[16] - The impact of exchange rate changes on cash was a negative 5.32 million, reflecting the depreciation of the Renminbi[16] Changes in Receivables and Payables - Other receivables decreased by 67.92% to 11.58 million, primarily due to the receipt of asset disposal payments and export tax rebates[16] - Prepayments increased by 51.13% to 116.83 million, mainly due to an increase in advance payments received[16] - Tax payable decreased by 38.86% to 60.82 million, primarily due to tax payments made during the period[16] Expenses - Sales expenses rose by 81.27% to 344.66 million, mainly due to increased marketing expenses[16] - Financial expenses increased by 117.05% to 70.06 million, primarily due to increased foreign exchange losses[16] Corporate Governance - The company reported no significant non-operational fund occupation by controlling shareholders or related parties during the reporting period[22]